Amgen 2001 Annual Report Download - page 4

Download and view the complete annual report

Please find page 4 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

Consolidated Statement of Operations Data
(In millions, except per share data)
Years ended December 31, 2001 2000 1999
Revenues:
Product sales
(1)
$3,511.0 $3,202.2 $3,042.8
Other revenues 504.7 427.2 297.3
Total revenues 4,015.7 3,629.4 3,340.1
Research and development expenses 865.0 845.0 822.8
Selling, general, and administrative expenses 970.7 826.9 654.3
Other items, net
(2)
203.1 (18.8) (49.0)
Net income 1,119.7 1,138.5 1,096.4
Diluted earnings per share
(2)
1.03 1.05 1.02
Cash dividends per share ———
Consolidated Balance Sheet Data
(In millions)
At December 31, 2001 2000 1999
Total assets $6,443.1 $5,399.6 $4,077.6
Long-term debt 223.0 223.0 223.0
Stockholders’ equity 5,217.2 4,314.5 3,023.5
(1)
Due to Year 2000 contingency planning in the fourth quarter of 1999, the Company offered extended payment terms on limited shipments of EPOGEN
®
(Epoetin alfa) and
NEUPOGEN
®
(Filgrastim) to certain wholesalers. These Year 2000 related sales totaled $45 million, or $0.02 per share, in 1999.
(2)
The amount in 2001 is primarily related to the costs of terminating collaboration agreements with various third parties. The amounts in 2000 and 1994 include write-offs of
acquired in-process research and development of $30.1 million and $116.4 million, respectively. The amount in 2000 also includes a charitable contribution of $25 million
to the Amgen Foundation and a $73.9 million benefit related to a legal proceeding. The amounts in other years are comprised of benefits and expenses related to various legal
proceedings. See Notes 4 and 11 to the Consolidated Financial Statements for a discussion of the amounts in 2001, 2000, and 1999. In 2001, the amount in Other items, net
combined with an inventory write-off of $39.5 million recorded in cost of sales decreased earnings per share by $0.15. Other items, net increased/(decreased) earnings per share
by $0.00 in 2000, $0.03 in 1999, $0.01 in 1998, ($0.09) in 1997, ($0.10) in 1994, $0.01 in 1993, and $0.04 in 1992.
Selected Financial Information
92 93 94 95 96 97 98 99 00 01
Total Revenues
($ in millions)
2001 $4,015.7
2000 3,629.4
1999 3,340.1
1998 2,718.2
1997 2,401.0
1996 2,239.8
1995 1,939.9
1994 1,647.9
1993 1,373.8
1992 1,093.0
92 93 94 95 96 97 98 99 00 01
Net Income
($ in millions)
2001 $1,119.7
2000 1,138.5
1999 1,096.4
1998 863.2
1997 644.3
1996 679.8
1995 537.7
1994 319.7
1993 383.3
1992 357.6
92 93 94 95 96 97 98 99 00 01
Diluted Earnings Per Share
2001 $1.03
2000 1.05
1999 1.02
1998 0.82
1997 0.59
1996 0.61
1995 0.48
1994 0.29
1993 0.33
1992 0.30
2